# First Tracks Biotherapeutics to Release Phase 1b Celiac Disease Trial Results

- URL: https://stocks.freetheai.org/news/first-tracks-biotherapeutics-to-release-phase-1b-celiac-disease-trial-results-73fa93
- Published: 2026-10-11T20:00:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:TRAX](https://stocks.freetheai.org/symbols/NASDAQ-TRAX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) plans to publish initial findings from Cohort 1 of its global Phase 1b study evaluating ANB033 in celiac disease. The drug, a CD122 antagonist, was tested in a gluten-challenge study designed to determine whether it can prevent mucosal damage.

The upcoming presentation provides market participants and healthcare professionals with early clinical evidence on ANB033. Beyond celiac disease, First Tracks Biotherapeutics is also developing the antibody treatment for eosinophilic esophagitis as part of its pipeline targeting autoimmune and inflammatory disorders.

The company will release the top-line results in a morning statement on Monday, October 12, 2026, followed by a live webcast and investor conference call at 8:30 a.m. Eastern Time. Shares of First Tracks Biotherapeutics recently traded at $31.85, down 0.50% on the day.

## Key points

- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) will report Phase 1b trial results for ANB033 on October 12, 2026.
- The Cohort 1 trial evaluates whether ANB033 prevents mucosal damage in celiac disease patients undergoing a gluten challenge.
- Management will discuss the top-line findings during a live webcast at 8:30 a.m. Eastern Time.
- First Tracks Biotherapeutics stock recently traded down 0.50% at $31.85.

## Questions and answers

### When will First Tracks Biotherapeutics report ANB033 trial data?

First Tracks Biotherapeutics will publish top-line Phase 1b data for ANB033 on Monday, October 12, 2026, prior to an 8:30 a.m. Eastern Time investor webcast.

### What is ANB033 and what condition does it target?

ANB033 is an experimental CD122 antagonist antibody in clinical development by First Tracks Biotherapeutics for celiac disease and eosinophilic esophagitis.

### How can investors access the First Tracks Biotherapeutics webcast?

Investors can join the live webcast on the investor relations section of the First Tracks Biotherapeutics website on October 12, 2026, at 8:30 a.m. Eastern Time.